KDR and gastric cancer: Recently, several drugs have been shown to increase survival against placebo in advanced GC; apatinib, a small selective VEGFR2 tyrosine kinase inhibitor, is now approved in China,[34] nivolumab, a monoclonal antibody inhibitor of programmed death-1, is approved in Japan[35,36] and, more recently, trifluridine/tipiracil, a novel oral combination cytotoxic drug, also known as TAS-102.[37] Although these treatments are effective, the absolute survival benefit is only 2 to 3 months compared to the control group.